Vasomotor symptoms in women over 60: results from the Data Registry on Experiences of Aging, Menopause, and Sexuality (DREAMS)

David, Paru S.; Kling, Juliana M.; Vegunta, Suneela; Faubion, Stephanie S.; Kapoor, Ekta; Mara, Kristin C.; Schroeder, Darrell R.; Hilsaca, Karla Frohmader; Kuhle, Carol L.

doi:10.1097/gme.0000000000001126

Cited by 17 publications

(9 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many women continue to report vasomotor symptoms beyond age 60, with over 40% of women aged 60 -65 reporting moderate to severe VMS (13,109). For those women with persistent bothersome symptoms, a discussion about benefits of HT relief vs risks associated with continuing HT beyond age 60 is warranted.…”

Section: Persistent Symptomsmentioning

confidence: 99%

Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts

2021

Self Cite

View full text Add to dashboard Cite

Menopausal hormone therapy (HT) prescribing practices have evolved over the last few decades guided by the changing understanding of the treatment’s risks and benefits. Since the Women’s Health Initiative (WHI) trial results in 2002, including post-intervention analysis and cumulative 18-year follow up, it has become clear that the risks of HT are low for healthy women less than age 60 or within ten years from menopause. For those who are experiencing bothersome vasomotor symptoms, the benefits are likely to outweigh the risks in view of HT’s efficacy for symptom management. HT also has a role in preventing osteoporosis in appropriate candidates for treatment. A comprehensive overview of the types, routes, and formulations of currently available HT, as well as HT’s benefits and risks by outcomes of interest are provided to facilitate clinical decision making.

show abstract

Section: Persistent Symptomsmentioning

confidence: 99%

Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts

2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Approximately 60% to 80% of women experience VMS during the menopause transition, 1,2 which averages 7 to 9 years, although some continue to have VMS in their 70s and 80s. [2][3][4][5] These symptoms can be associated with a decrease in quality of life, often manifested as sleep disturbance, depression, and even mental exhaustion. [1][2][3][4][5][6] Demographic and socioeconomic factors can affect VMS frequency and intensity.…”

Section: ■ the Epidemiology Of Vasomotor Symptomsmentioning

confidence: 99%

“…[2][3][4][5] These symptoms can be associated with a decrease in quality of life, often manifested as sleep disturbance, depression, and even mental exhaustion. [1][2][3][4][5][6] Demographic and socioeconomic factors can affect VMS frequency and intensity. The Study of Women Across the Nation 7 revealed that Black women have the highest prevalence REVIEW…”

mentioning

confidence: 99%

Stellate ganglion block as a treatment for vasomotor symptoms: Clinical application

Lee

Wie

Pew

et al. 2022

CCJM

Self Cite

View full text Add to dashboard Cite

V asomotor symptoms (vms), also called hot fl ashes, hot fl ushes, and night sweats, are common symptoms of menopause. 1 They are described as moments of intense heat, usually accompanied by sweating and fl ushing in the upper body, including the head, neck, and upper torso, 1 and they are associated with poor health outcomes and decreased quality of life. While hormonal therapies are the mainstay of treatment for VMS, there is a clear need for safe and effective nonhormonal treatment options for women who choose not to use hormone therapy and for those in whom hormone therapy is not effective.Stellate ganglion block (SGB) is a promising alternative nonhormonal treatment. In this review, we describe the evidence supporting its use in the management of VMS in perimenopausal and postmenopausal women, particularly in those who have severe symptoms refractory to more conservative care. ■ THE EPIDEMIOLOGY OF VASOMOTOR SYMPTOMSApproximately 60% to 80% of women experience VMS during the menopause transition, 1,2 which averages 7 to 9 years, although some continue to have VMS in their 70s and 80s. [2][3][4][5] These symptoms can be associated with a decrease in quality of life, often manifested as sleep disturbance, depression, and even mental exhaustion. [1][2][3][4][5][6] Demographic and socioeconomic factors can affect VMS frequency and intensity. The Study of Women Across the Nation 7 revealed that Black women have the highest prevalence REVIEW

show abstract

“…The BEERS Criteria are also applied to the use of low-dose vaginal estrogen therapies for treatment of GSM despite the fact that systemic absorption is minimal with vaginal inserts, tablets, and rings, 23 and the use of these products is not associated with long-term adverse events in observational studies 46,47 . In addition, vasomotor symptoms commonly persist beyond the age of 60 years, and GSM symptoms tend to worsen rather than improve over time 22,48,49 . Further, the FDA's policy of using class labeling for estrogen-containing products does not allow for accurate differentiation between the risks associated with systemic estrogen therapies and low-dose vaginal therapies, leading to overestimation of risk associated with low-dose vaginal therapies and avoidance of highly effective treatment for GSM by many women.…”

Section: How Do We Close the Menopause Care Gap?mentioning

confidence: 99%

The Menopause Management Vacuum

Faubion

Shufelt

2022

Cancer J

Self Cite

View full text Add to dashboard Cite

The burden of untreated menopause symptoms in midlife women is substantial and can result in reduced quality of life as well as lost work productivity, lost opportunities for advancement at work, and increased health care costs. Unfortunately, the health care system is largely unprepared to help women manage these symptoms, which have a mean duration of 7 to 9 years. Hormone therapy usage rates have plummeted following publication of the results of the Women's Health Initiative trials due to safety concerns. In addition, postgraduate medical training programs include minimal to no training on menopause management. These and other factors have contributed to what is essentially a menopause management vacuum. This vacuum created a market opportunity, particularly given the fact that midlife women are potent drivers of the global economy. In this review, we outline the menopause management gaps and discuss a multipronged approach to close these gaps and improve the care of midlife women.

show abstract

Vasomotor symptoms in women over 60: results from the Data Registry on Experiences of Aging, Menopause, and Sexuality (DREAMS)

Abstract: A substantial number of women seen in a specialty menopause clinic were over age 60 years and reported msVMS, highlighting that VMS may be disruptive in women over a decade past the natural age of menopause.

Cited by 17 publications

References 44 publications

Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts

Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts

Stellate ganglion block as a treatment for vasomotor symptoms: Clinical application

The Menopause Management Vacuum

Contact Info

Product

Resources

About